close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,425.17 -7.12 (-0.50%)
Delayed Quote Updated: 12:24 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
Topics Energy
News headline image
Is Eli Lilly Stock a Buy Right Now? ↗
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next. 
Via The Motley Fool
News headline image
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ↗
Is this company the biggest dark horse in the chronic weight management space? 
Via The Motley Fool
Eli Lilly & Co (NYSE:LLY) Offers Dividend Quality for Growth-Focused Income Investors ↗
Via Chartmill
News headline image
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs ↗
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector. 
Via MarketBeat
Topics ETFs
News headline image
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗
Buffett has warned about "gambling" in the market. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735. 
Via The Motley Fool
News headline image
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade? ↗
Novo is facing some headwinds, but it has a plan to overcome them. 
Via The Motley Fool
News headline image
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗
It was Griffin's biggest add for Citadel last quarter. 
Via The Motley Fool
Topics Economy
News headline image
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗
The gene-editing biotech stock is down more than 12% this year. 
Via The Motley Fool
Topics ETFs Lawsuit
News headline image
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys ↗
These funds can help you weather any storm that might be on the way. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher ↗
Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine. 
Via The Motley Fool
News headline image
Novo Nordisk and Eli Lilly Just Got Some Fantastic News ↗
A new government-funded study found that GLP-1 drugs slow the aging process in mice. 
Via The Motley Fool
News headline image
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? ↗
The Lilly Foundation is unloading 300,000 shares of the stock. 
Via The Motley Fool
News headline image
Stock Split Watch: Is Eli Lilly Next? ↗
The stock has soared 25% in six months. 
Via The Motley Fool
News headline image
Meet the Low-Cost Vanguard ETF With Taiwan Semiconductor, Samsung Electronics, SK Hynix, and ASML as Its 4 Largest Holdings ↗
International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
5 Stocks to Start With if You Only Have $1,000 ↗
Even if you add nothing at all, $1,000 can accomplish a lot over decades. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
What Is Market Cap? The Definition Every Investor Needs Before Picking Their First Stock ↗
Different categories offer different benefits for investors. 
Via The Motley Fool
Topics Artificial Intelligence
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq ↗
Via Chartmill
Topics Economy
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% ↗
On Oct. 14, 2026, a hotter-than-expected CPI report pressures growth stocks and the semiconductor selloff continues. 
Via The Motley Fool
Topics Artificial Intelligence Bonds Economy
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Meet the Vanguard ETF That Has Outperformed the Market Nearly 64% of the Time -- and Will Likely Continue Doing So ↗
It's banking on winners continuing to run. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor ↗
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said... 
Via MarketBeat
Topics Intellectual Property
News headline image
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate. 
Via The Motley Fool
News headline image
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years ↗
These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future. 
Via The Motley Fool
News headline image
Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)? ↗
FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter. ↗
Eli Lilly's next big growth driver could be bigger than Zepbound. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.